ABSTRACT The relative roles of prostaglandins and the sympathetic nervous system in mediating the hypotensive effects of hydralazine were studied in awake dogs with and without pretreatment with indomethacin, propranolol, and phentolamine. In normal dogs, mean aortic pressure decreased 23 ± 4 mm Hg after administration of hydralazine (cumulative dose of 0.8 mg/kg). This hypotensive effect of hydralazine was potentiated by phentolamine but was abolished by propranolol. Indomethacin caused a paradoxic pressor response (1 1 + 3 mm Hg) to hydralazine, which also was abolished by addition of phentolamine. Hydralazine produced vasodilation in the coronary, skeletal muscle (quadriceps), splanchnic, and renal circulations in normal dogs. The increase in coronary blood flow was associated with increased cardiac oxygen consumption and narrowed arteriovenous oxygen difference across the heart. Propranolol reduced the increases in cardiac oxygen consumption and coronary blood flow, but only indomethacin abolished the narrowed arteriovenous oxygen difference, suggesting that the increase in coronary blood flow was related to both the increased cardiac oxygen demand and prostaglandin-mediated active coronary vasodilation. The decrease in skeletal muscle vascular resistance after hydralazine was abolished by propranolol. Skeletal muscle vascular resistance actually increased after administration of hydralazine in dogs pretreated with both propranolol and indomethacin. These effects were blocked by the addition of phentolamine. Unlike the normal response, renal and splanchnic vascular resistances increased after administration of hydralazine in dogs pretreated with indomethacin. The splanchnic vasoconstriction was abolished by phentolamine, but the renal vascular change was affected by neither phentolamine nor propranolol. The results indicate that hydralazine does not produce uniform vasodilation in all organs and that the cardiovascular actions of hydralazine involve both prostaglandins and the sympathetic nervous system. Circulation 70, No. 5, 908-916, 1984. HYDRALAZINE is a vasodilator used commonly for the treatment of hypertension and congestive heart failure, but the mechanism by which it exerts the vasodilative action has not been clearly defined. Hydralazine has been shown to exert a direct relaxant effect on
vascular smooth muscle,1-' and this effect appears to be dependent on intact endothelium.3 However, part of its action is probably mediated via increased production of prostaglandins, because its hypotensive effect is abolished by a variety of prostaglandin synthetase inhibitors.4 5 In addition, hydralazine causes sympathetic stimulation via both a direct action of the drug on the release of endogenous catecholamines6 7 and a reflex change resulting from withdrawal of baroreceptor activation. 8 This sympathetic activation may cause cardiac stimulation, but whether it contributes significantly to the vascular effects of the drug is unknown. Furthermore, the actions of hydralazine on regional vascular beds have not been adequately studied. Hydralazine may not exert uniform vasodilation, and each organ may have a different controlling mechanism for its blood flow response to hydralazine. Thus, to examine LABORATORY INVESTIGATION-PHARMACOLOGY the relative roles of endogenous prostaglandins and the sympathetic nervous system in mediating the cardiovascular effects of hydralazine, we performed the present study in awake dogs with and without pretreatment with indomethacin and adrenergic receptor-blocking agents. Both systemic and regional hemodynamics were measured to analyze systematically the mechanisms and sites of action of the drug.
Methods
Adult dogs weighing 8.2 to 15.4 kg were sedated with subcutaneous morphine sulfate (0.5 mg/kg) and placed in a right decubitus position. After limb electrodes had been placed to monitor electrocardiograms, four catheters were inserted with use of local anesthesia (0.5% lidocaine) and fluoroscopic guidance into the descending aorta, the pulmonary artery, coronary sinus, and left ventricle. The descending aorta and pulmonary artery were cannulated with a No. 8F Coumard catheter via a femoral artery and with a No. 7F Swan-Ganz catheter via an external jugular vein, respectively. The coronary sinus was cannulated with a No. 7F catheter via the other external jugular vein. All catheters were connected to Statham P23Db pressure transducers and a multichannel Brush 480 recorder (Gould Inc., Instrument Systems Division) for measuring aortic, pulmonary arterial, and coronary sinus blood pressures and for collecting blood samples. Mean pressures were obtained by electronic integration. A superficial hindlimb vein was cannulated with a polyethylene catheter for administration of drugs.
Cardiac output was measured by an indocyanine green (Cardio-Green; Hynson, Westcott & Dunning, Inc.) dye-dilution technique, with a Gilford model 140 cardiac output system (Gilford Instrument Laboratories, Inc.). Regional blood flow was measured by a modified radioactive microsphere method.9 A total of 0.5 to 1.0 million microspheres, 15 + 3 gm in diameter and labeled with cerium-14 1, tin-113, ruthenium-103, niobium-95, and scandium-46 at a specific activity of 10 mCi/g (New England Nuclear), were injected into the left ventricle, followed by a flush of 10 ml of normal saline. The microspheres, suspended in 10% dextran, were sonicated and agitated vigorously on a Vortex mixer immediately before use. Arterial reference blood was collected at a rate of 7.75 ml/min by a Harvard pump (Harvard Apparatus Co., Inc.), beginning 10 sec before the commencement of microsphere injection and continuing for 80 sec thereafter. Radioactivity in organs and reference blood samples was counted with a Packard gamma spectrometer and a model 9012 multichannel analyzer at appropriate window settings corresponding to the peak energy of the nuclides used. The activity of each isotope was corrected for background, and crossover activity from other isotopes was eliminated by simultaneous equations. Absolute blood flow was calculated by the reference sample method on a PDP-11 minicomputer (Digital Equipment Corp.) as follows: organ blood flow (ml/l00 g/min) = [arterial reference flow (ml/min) x organ radionuclide activity x 100]/[arterial reference blood radionuclide activity X organ weight (g)]. Total splanchnic blood flow was calculated by summation of blood flows to stomach, spleen, small and large intestines, and liver (hepatic arterial blood flow). Total peripheral or regional organ vascular resistances were calculated as mean aortic pressure divided by cardiac output or regional blood flow (dyne-sec-cm-5). Total ventricular work and myocardial oxygen consumption were calculated by the conventional formulas.
Blood samples were obtained simultaneously from aorta and coronary sinus for measuring oxygen contents on a Lex-02-Con analyzer (Lexington Instruments). Arterial blood samples were also taken for measuring plasma catecholamines,'0 and pH, Po2, and Pco2 with a Radiometer PHM71 Acid Base Analyzer (Rainin Instrument Co.).
Experimental protocol. Experiments were begun 2 to 3 hr after administration of morphine and at least 45 min after all catheters had been in place. To study the role of prostaglandins in mediating the cardiovascular actions of hydralazine, animals were divided into two major groups. One group of animals was pretreated with indomethacin to inhibit prostaglandin synthesis, and the other group was given normal saline (100 ml) as control. Indomethacin and saline were given 30 min before taking baseline measurements. Indomethacin (Sigma Chemical Co.), 10 mg/kg dissolved with an equimolar amount of sodium carbonate in 100 ml normal saline before each use, was administered intravenously over a 5 min period. Animals in each major group were further divided into three or four subgroups. One subgroup received no additional pretreatment, the second received phentolamine (8 gg/kg/min), the third was pretreated with propranolol (1.5 mg/kg, iv), and the fourth received both phentolamine and propranolol. Propranolol was given 30 min before the experiment. Concentrations of phentolamine were adjusted for body weight in each experiment, and the infusion was begun immediately after indomethacin or saline pretreatment and continued throughout the experiment at a rate of 0.9 ml/min with a Harvard pump.
Thus hydralazine was administered to seven groups of animals divided according to their pretreatments: group 1 (n = 9, 12 + 1 kg), saline (normal); group 2 (n = 6, 11 ± 1 kg), phentolamine; group 3 (n = 7, 12 + 1 kg), propranolol; group 4 (n = 7, 1 1 + 1 kg), phentolamine and propranolol; group 5 (n = 7, 12 + 1 kg), indomethacin; group 6 (n -7, 12 + 1 kg), indomethacin and propranolol; group 7 (n -5, 13 + 1 kg), indomethacin, phentolamine, and propranolol. There were no differences in the experimental protocols other than the pretreatments among the groups. The efficacies of propranolol and phentolamine in producing ,B-and a-receptor blockade were determined by giving isoproterenol and norepinephrine, respectively, before the administration of adrenergic-blocking agents and at the end of the experiment. "' The adequacy of indomethacin in blocking the formation of prostaglandins was assessed by measuring the hypotensive effects of intravenous sodium arachidonate (3 mg; Sigma) before and after pretreatment with indomethacin.
After baseline measurements had been obtained over a 20 min period, serial doses of hydralazine (0.1, 0.1, 0.2, and 0.4 mg/ kg) were administered intravenously at 30 min intervals, yielding cumulative doses of hydralazine of 0.1, 0.2, 0.4, and 0.8 mg/kg after each dose of hydralazine. Systemic hemodynamics were measured at 5 min intervals throughout the experiment. Regional blood flow and blood gas measurements were taken between 25 and 30 min after each dose of hydralazine. Plasma catecholamines were measured in normal dogs after each hydralazine dose.
In addition, five dogs (12 + 1 kg) that received no pretreatment were given normal saline instead of hydralazine. They served as a sham control group.
At the end of the experiment, the animals were killed by a lethal dose of sodium pentobarbital. The heart, brain, stomach, small intestine, large intestine, liver, pancreas, spleen, kidneys, and quadriceps muscle were removed, cleaned, weighed, and prepared for radioactivity counting to determine regional blood flow.
Statistics. Results are expressed as mean + SE. The experimental results were treated statistically with two-way analysis of variance for independent groups with trend analysis.'2 The significance of differences between the control and experimen- increase was significantly smaller in the last group than in the normal dogs. Propranolol abolished the increase in cardiac output. Table 1 shows that propranolol and indomethacin attenuated the hydralazine-induced decrease in total peripheral vascular resistance. Addition of phentolamine to propranolol in group 4 unmasked the hypotensive effect of hydralazine and allowed total peripheral vascular resistance to decrease as it did in normal dogs. Cardiac output increased only slightly in this group. As in group 5, hydralazine produced a pressor response in group 6 (indomethacin plus propranolol), but neither cardiac output nor total peripheral vascular resistance changed significantly. Hydralazine did not affect aortic blood pressure in the group with the combined pretreatment with indomethacin, propranolol, and phentolamine (group 7), which also diminished the increase in cardiac output and the decrease in total peripheral vascular resistance. Table 1 further shows that the increase in heart rate produced by hydralazine was unaffected by phentolamine (group 2) but was reduced by indomethacin and propranolol in groups 3 through 7.
Hydralazine increased plasma levels of both norepinephrine (0.30 ± 0.06 to 0.64 + 0.13 ng/ml) and epinephrine (0.78 ± 0.20 to 1.91 ± 0.73 ng/ml) in normal dogs. It also increased arterial blood pH (7.42 ± 0.02 to 7.50 + 0.02) and decreased Pco2 (33 ± 2 to 24 ± 2 mm Hg), probably because of respiratory stimulation by hydralazine.
Coronary hemodynamic effects of hydralazine. Hydralazine increased left ventricular blood flow and myocardial oxygen consumption and decreased coronary vascular resistance in the normal dogs (table 2) . Left ventricular work increased significantly from 8.3 ± 0.4 to 12.2 ± 1.4 kg-m/min. Simultaneously, coronary sinus oxygen saturation increased from 20 ± 2% to 36 ± 2% and myocardial oxygen extraction decreased. These changes were unaffected by phentolamine. On the other hand, propranolol pretreatment (groups 3 and 4) abolished the increase in myocardial oxygen consumption produced by hydralazine but did not prevent myocardial oxygen extraction from decreasing. Propranolol also reduced the increase in left ventricular blood flow and the decrease in vascular resistance that occurred in normal dogs. Indomethacin increased baseline left ventricular blood flow and decreased coronary vascular resistance in group 5. It also reduced the hydralazine-induced increases in left ventricular blood flow and myocardial oxygen consumption. The remaining increase in myocardial oxygen consumption produced by hydralazine was abolished by addition of propranolol (groups 6 and 7). As in group 5, left ventricular blood flow increased slightly after hydralazine in groups 6 and 7. Coronary vascular resistance did not change in groups 5 and 6 but decreased significantly in group 7. Unlike its effect in groups 1 through 4, hydralazine did not significantly alter myocardial oxygen extraction in any of the groups pretreated with indomethacin.
Other organ vascular responses to hydralazine. The effects of inhibition of prostaglandin synthesis and 912 adrenergic receptor blockade on organ vascular responses to hydralazine are summarized in tables 3 to 5. Hydralazine caused vasodilation in quadriceps muscle, kidneys, and viscera in normal dogs. Table 3 shows that neither. phentolamine nor indomethacin affected the increase in blood flow or the decrease in vascular resistance in the skeletal muscle produced by hydralazine, but these responses were abolished by propranolol. Moreover, hydralazine caused a marked increase in skeletal muscle vascular resistance and a decrease in skeletal muscle blood flow in group 6. These effects of propranolol, however, were absent when phentolamine was added (groups 4 and 7).
Phentolamine did not significantly alter the decrease in splanchnic vascular resistance that occurred after hydralazine (table 4) . This decrease in splanchnic vascular resistance, however, was abolished by propranolol. Addition of phentolamine (group 4) unmasked the effect of propranolol. The splanchnic vascular response to hydralazine also was affected by indomethacin. Splanchnic blood flow decreased and vascular resistance increased after hydralazine in dogs pretreat-CIRCULATION ed either with indomethacin alone (group 5) or with both indomethacin and propranolol (group 6). The effects of indomethacin were also abolished by the addition of phentolamine (group 7), suggesting that the increase in splanchnic vascular resistance was mediated via a-adrenergic receptors. Table 5 shows that unlike the normal group, renal blood flow decreased after hydralazine in groups 2, 5, and 7. The decrease in renal vascular resistance that occurred after hydralazine in normal dogs did not occur in groups 2 to 7. Renal vascular resistance actually increased after hydralazine in the indomethacin-pretreated dogs (groups 5 through 7). However, unlike the change in splanchnic vascular resistance, this increase in renal vascular resistance was unaffected by additions of propranolol and phentolamine (groups 6 and 7).
Hemodynamic changes in the sham-treated dogs. Five sham-treated animals that received normal saline instead of hydralazine did not show significant systemic and regional hemodynamic changes. Plasma catecholamines and arterial blood gases also did not change significantly over the experimental period.
Discussion
Hypotensive effect of hydralazine. The results of this study show that pretreatment with indomethacin abolished the decrease in aortic pressure and attenuated the decrease in total peripheral vascular resistance produced by hydralazine in awake dogs. These results are consistent with the findings in anesthetized dogs that the hypotensive effects of hydralazine and dihydralazine were reversed by a variety of prostaglandin synthetase inhibitors like indomethacin, diclofenac, acetylsalicylate, and flufenamate.4' Indomethacin also attenuates the antihypertensive effect of hydralazine in renal hypertensive rats, 14 the vasodilative effect Vol. 70, No. 5, November 1984 of dihydralazine in patients with essential hypertension,'5 and the pulmonary vasodilative effect of hydralazine during hypoxia-induced pulmonary vasoconstriction in dogs. 16 However, inhibition of prostaglandin synthesis does not abolish the vasodilative effect of clonidine, prazosin, or guanethidine. Similarly, we'7 have recently demonstrated that indomethacin does not affect the hypotensive action of a new antihypertensive agent, pinacidil. Thus it appears that the effect of indomethacin on blood pressure response is specific for hydralazine and dihydralazine and that prostaglandins play an important role in mediating the hypotensive effect of these agents.
The mechanism by which hydralazine produces prostaglandin-mediated vasodilation has not been fully elucidated. Hydralazine has been shown to decrease thromboxane A2 and increase prostaglandin '2 production. '8' 19 This action of hydralazine may relate to the chelating property of the drug. It is speculated that because lipoxygenase is an iron-dependent enzyme,20 hydralazine may inhibit the action of lipoxygenase and reduce the formation of 1 5-hydroperoxyeicosatetraenoic acid (HPETE). Since HPETE is a potent inhibitor of prostacyclin synthetase,2' administration of hydralazine may result in disinhibition of prostacyclin synthetase and increased production of prostacyclin. This increase in prostacyclin may contribute to the hypotensive action of hydralazine. However, because these studies were conducted with very large doses of hydralazine, their relevance to therapeutic doses of hydralazine remains unclear.
Our results further show that the hypotensive effect of hydralazine was abolished by propranolol. This is in contrast to the results of other investigators, who found no major influence on the hydralazine-induced hypotension by propranolol.4'5 This difference is probably related to the use of anesthesia by the prior investiga-913 23. 24 Our study indicates that hydralazine stimulates the sympathetic nerves and adrenal medulla, as evidenced by the increases in both plasma norepinephrine and epinephrine. The catecholamine release may result either from a tyramine-like effect of hydralazine6,7 or from sympathetic reflex activation secondary to the hypotensive effect of the drug.8 The sympathetic stimulation is probably responsible, at least in part, for the increases in heart rate and cardiac output after hydralazine, both of which were either reduced or abolished by propranolol. The residual increase in heart rate after /3-receptor blockade was probably caused by the vagolytic component to the baroreceptor reflex. Indomethacin pretreatment also blunted the responses of heart rate and cardiac output to hydralazine. This effect probably was related to the paradoxic pressor response in these animals, which obviated the usual hypotension-induced reflex release of catecholamines.
The vasodilative effect of hydralazine probably also results in part from /3-receptor-mediated vasodilator action of catecholamines. However, adrenergic a-receptor-mediated vasoconstriction may offset the hydralazine-induced hypotension if /3-vasodilation is abolished. This explains why phentolamine potentiated while propranolol abolished the hypotensive effect of hydralazine. The a-vasoconstriction was also responsible for the increase in mean aortic blood pressure after hydralazine in the dogs pretreated with indomethacin and indomethacin plus propranolol, since this pressor response was abolished by addition of phentolamine. On the other hand, the hypotensive effect of hydralazine has been shown to be independent of sympathetic innervation in manY25 Our study also shows that total peripheral vascular resistance still de- The directional changes are indicated by upward arrows for increases, downward arrows for decreases, and dashes for no changes. The number of arrows in each column indicates the relative degree of changes among the groups.
caused, at least in part, by a direct. catecholaminereleasing action of hydralazine. The increase in renal vascular resistance produced by hydralazine in the indomethacin-pretreated dogs, however, was not caused by a-vasoconstriction because it was unaffected by the addition of phentolamine (group 7). Most likely it is related to the local production of angiotensin26' 27 or other renal constrictor substances such as adenosine triphosphate or adenosine.228.29 Finally, our findings further indicate that the hypotensive efficacy of hydralazine may be greatly influenced by disease states or by concurrent medications that alter sympathetic activity or the production of prostaglandins.
